Next Article in Journal
Re-Evaluating Biologic Pharmacotherapies That Target the Host Response during Sepsis
Previous Article in Journal
Bone Pain in Cancer Patients: Mechanisms and Current Treatment
Open AccessArticle

Decreased Activity of Blood Acid Sphingomyelinase in the Course of Multiple Myeloma

Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14, 02-776 Warsaw, Poland
Department of Microbiology and Immunology, The Faculty of Medicine and Health Sciences of the Jan Kochanowski University in Kielce, Stefana Żeromskiego 5, 25-001 Kielce, Poland
Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland
Holy Cross Cancer Center, Artwinskiego 4, 25-734 Kielce, Poland
Regional Blood Transfusion Center in Bialystok, 15-950 Bialystok, Poland
Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(23), 6048;
Received: 8 November 2019 / Accepted: 27 November 2019 / Published: 30 November 2019
(This article belongs to the Section Molecular Oncology)
Acid sphingomyelinase (aSMase) is involved in the generation of metabolites that function as part of the sphingolipid signaling pathway. It catalyzes the breakdown of sphingomyelin into ceramide, a bioactive lipid that, among other roles, is involved in regulation of apoptosis. Dry drop blood test (DBS) and colorimetric 2-step enzymatic assay were used to assess the activity of human blood aSMase, beta-galactosidase, and beta-glucosidase, these enzymes are lysosomal hydrolases that catalyze the degradation of related sphingolipids, of sphingolipid signaling molecules. Blood was collected from a group of healthy volunteers and patients that were diagnosed with multiple myeloma (MM) in various stages of the disease. Additionally, activity of those enzymes in patients diagnosed with other hematological cancers was also assessed. We found that aSMase activity in the blood of patients with MM (at the time of diagnosis) was 305.43 pmol/spot*20 h, and this value was significantly lower (p < 0.030) compared to the healthy group 441.88 pmol/spot*20 h. Our collected data suggest a possible role of aSMase in pathogenesis of MM development. View Full-Text
Keywords: myeloma multiple; sphingolipids; acid sphingomyelinase; cell signaling myeloma multiple; sphingolipids; acid sphingomyelinase; cell signaling
Show Figures

Figure 1

MDPI and ACS Style

Wątek, M.; Piktel, E.; Barankiewicz, J.; Sierlecka, E.; Kościołek-Zgódka, S.; Chabowska, A.; Suprewicz, Ł.; Wolak, P.; Durnaś, B.; Bucki, R.; Lech-Marańda, E. Decreased Activity of Blood Acid Sphingomyelinase in the Course of Multiple Myeloma. Int. J. Mol. Sci. 2019, 20, 6048.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop